Shares in Novo Nordisk were up nearly 12% today – hiking ... The new results with a once-weekly subcutaneous injection of amycretin – which is also being developed in a daily oral formulation ...
Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat ...